Sentinel Offers Drug Firms ‘Unique’ Venue For Post-Market Studies, Pfizer Says
Pfizer’s experience in piloting an approach to using US FDA’s Sentinel data network for post-market research demonstrated the feasibility and benefits of doing so.
You may also be interested in...
Lilly used Reagan-Udall’s IMEDS to tap Sentinel for data on incidence of venous thromboembolism in patients with rheumatoid arthritis.
One of the faces of FDA's effort to recruit senior leaders from outside its walls has decided to return to industry.
Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.